Constipation-predominant Irritable Bowel Syndrome Clinical Trial
Official title:
Laser Acupuncture for Treatment of Female Patients With Irritable Bowel Syndrome:RCT
The aim of the study to investigate effect of laser acupuncture on constipation predominant irritable bowel syndrome in female patients
Irritable bowel syndrome (IBS) is a common chronic functional gastrointestinal disorder characterized by recurrent abdominal pain and/or bloating related to defecation without reliable biological markers . IBS is associated with substantial burden, such as higher levels of anxiety, lost productivity at work, work absenteeism (Pimentel, 2018). IBS has a strong predominance in women IBS-C includes a wide range of symptoms, and its pathophysiology is complex and not fully understood. Visceral hypersensitivity and delayed gut transit are recognized as major pathophysiological mechanisms in IBS-C. Visceral hypersensitivity may account for symptoms of abdominal pain, bloating, and discomfort. Delayed gut transit causes constipation The unsatisfactory treatment responses and adverse effects associated with pharmacologic therapies have resulted in a higher demand for alternative therapies Acupoints and manipulations are the same in both the experimental and the control groups. The participants in the control group will receive sham laser acupuncture treatment, without any laser output, while the participants in the experimental group will sequentially receive 0.375J of energy at each of the following acupoints: Baihui (GV20), Yintang (GV29), Taichong (LR3), Zusanli (ST36), Sanyinjiao (SP6), Tianshu (ST25), and Shangjuxu (ST37) acupoint .Using a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5W/cm2; pulsed wave; and Bahr frequencies [B1: 599.5Hz, B2: 1199Hz, B3: 2398Hz, B4: 4776Hz, B5: 9552 Hz, B6: 19,104Hz, and B7: 38,208Hz]. The laser treatment will be applied to each point for 5 seconds, to deliver a total treatment dose of 4.5J/cm2 . intervention will be 3t/ week for 6 weeks in both groups. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00742872 -
Randomized Trial of Mosapride Versus Placebo in the Treatment of Constipation-Predominant Irritable Bowel Syndrome
|
Phase 3 | |
Completed |
NCT05164861 -
Safety and Efficacy of Non-alcoholic Beverage Based on Kombucha in Patients With Constipations
|
N/A | |
Withdrawn |
NCT05321953 -
The Impact of Aerobic Interval and Inspiratory Muscle Training On Patient Reported Outcome Scores In Individuals With Chronic Constipation
|
N/A | |
Not yet recruiting |
NCT06319729 -
A Chinese Herbal Medicine for IBS-C
|
Phase 2 | |
Completed |
NCT01085643 -
Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)
|
N/A | |
Completed |
NCT03150212 -
Effect of Saccharomyces Cerevisiae on the Improvement of Gastro-intestinal Disorders Associated to IBS With C Phenotype
|
N/A | |
Completed |
NCT05392439 -
Effect of taVNS on Abdominal Pain and Other Symptoms in Constipation-predominant Irritable Bowel Syndrome
|
N/A | |
Not yet recruiting |
NCT05921383 -
Anorectal Manometry of Patients With Constipation Predominant IBS
|
||
Recruiting |
NCT05134584 -
Efficacy of Linaclotide in Patients With Overlapping Functional Gastrointestinal Disorders
|
Phase 4 | |
Terminated |
NCT03336034 -
Assessment of Responsiveness to Treatment by Experience Sampling Method
|
||
Not yet recruiting |
NCT04666155 -
MOWOOT Device Treatment for Adults With Chronic Constipation
|
N/A | |
Not yet recruiting |
NCT05941650 -
To Study the Effect of Short-chain Fructooligosaccharides in Women With Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT00945334 -
Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT00912301 -
Cheno Effect on Transit in Health and IBS-C
|
Phase 2 | |
Terminated |
NCT00607971 -
Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
|
Phase 3 |